| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H18FN7 |
| Molecular Weight | 399.4236 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(=N1)C2=C(N=C(CNC3=CC=CC=C3F)N2)C4=CN5N=CN=C5C=C4
InChI
InChIKey=FJCDSQATIJKQKA-UHFFFAOYSA-N
InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
| Molecular Formula | C22H18FN7 |
| Molecular Weight | 399.4236 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
EW-7197 is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity. EW-7197 is in phase I clinical trials for the treatment of solid tumors. Also, EW-7197 has a strong potential as an anti-fibrosis therapeutic agent.
Originator
Approval Year
Doses
Sourcing
PubMed
Patents
Sample Use Guides
Starting single daily dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm (once daily for 5 days followed by 2 days without treatment in 28-day cycles)
Route of Administration:
Oral
